Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -127.14% is 54% below its 5-year average of -82.73%, near the low end of its 5-year range (-143.18%–-28.46%).
1.55% above its 12-month average of -129.15%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -29.43%.
RETURN ON ASSETS (ROA)
-127.14%
RETURN ON ASSETS (ROA) AVG TTM
-129.15%
RETURN ON ASSETS (ROA) AVG 3Y
-91.50%
RETURN ON ASSETS (ROA) AVG 5Y
-82.73%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+1.55%
CURRENT VS 3Y AVG
-38.95%
CURRENT VS 5Y AVG
-53.68%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-294.35%
vs the sector median at left
Cardiol Therapeutics Inc.
Market Cap
$151.01M
Return on Assets (ROA)
-127.14%
TTM Avg
-129.15%
3Y Avg
-91.50%
5Y Avg
-82.73%
Market Cap
$149.36M
Return on Assets (ROA)
-50.30%
TTM Avg
-131.74%
3Y Avg
-92.52%
5Y Avg
-67.08%
Market Cap
$152.72M
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$148.73M
Return on Assets (ROA)
-96.78%
TTM Avg
-33.63%
3Y Avg
-87.61%
5Y Avg
-84.15%
Market Cap
$148.64M
Return on Assets (ROA)
-54.48%
TTM Avg
-32.00%
3Y Avg
-13.86%
5Y Avg
-13.02%
Market Cap
$153.58M
Return on Assets (ROA)
N/A
TTM Avg
-34.95%
3Y Avg
-49.76%
5Y Avg
-43.08%
Market Cap
$148.27M
Return on Assets (ROA)
-20.01%
TTM Avg
-38.20%
3Y Avg
-34.64%
5Y Avg
-39.69%
Market Cap
$153.79M
Return on Assets (ROA)
-23.14%
TTM Avg
-29.29%
3Y Avg
-29.10%
5Y Avg
-28.90%
Market Cap
$146.62M
Return on Assets (ROA)
-90.55%
TTM Avg
-70.80%
3Y Avg
-45.07%
5Y Avg
-40.08%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cardiol Therapeutics Inc. (CRDL) | $151.01M | -127.14% | -129.15% | -91.50% | -82.73% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $149.36M | -50.30% | -131.74% | -92.52% | -67.08% |
| Veraxa Biotech Holding AG (VRXA)vs › | $152.72M | N/A | N/A | N/A | N/A |
| Korsana Biosciences, Inc. (KRSA)vs › | $148.73M | -96.78% | -33.63% | -87.61% | -84.15% |
| Voyager Therapeutics, Inc. (VYGR)vs › | $148.64M | -54.48% | -32.00% | -13.86% | -13.02% |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $153.58M | N/A | -34.95% | -49.76% | -43.08% |
| Anavex Life Sciences Corp. (AVXL)vs › | $148.27M | -20.01% | -38.20% | -34.64% | -39.69% |
| Neuronetics, Inc. (STIM)vs › | $153.79M | -23.14% | -29.29% | -29.10% | -28.90% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.62M | -90.55% | -70.80% | -45.07% | -40.08% |
| Codexis, Inc. (CDXS)vs › | $146.28M | -25.59% | -36.78% | -35.70% | -27.05% |
ROA
-127.1%
ROE
-155.3%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -143.18% |
| 2024-12-31 | -115.11% |
| 2023-12-31 | -57.83% |
| 2022-12-31 | -49.87% |
| 2021-12-31 | -28.46% |
| 2020-12-31 | -101.94% |
| 2019-12-31 | -68.07% |
| 2018-12-31 | -64.39% |
| 2017-12-31 | -51.57% |
